Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_2
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

recruiting150%
not_yet_recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
not_yet_recruitingphase_2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

NCT07485010
recruitingphase_1

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

NCT06801223

Clinical Trials (2)

Showing 2 of 2 trials
NCT07485010Phase 2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not Yet Recruiting
NCT06801223Phase 1

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2